
Pfizer asked the Food and Drug Administration to authorize a second booster dose of its COVID-19 vaccine for adults age 65 and older who received an initial booster of any authorized or approved COVID-19 vaccine, based on data from Israel showing the additional booster reduced infections and severe illness when the omicron variant was circulating.